Previous Close | 31.14 |
Open | 31.37 |
Bid | 31.96 x 100 |
Ask | 32.11 x 100 |
Day's Range | 31.14 - 32.27 |
52 Week Range | 23.14 - 35.56 |
Volume | |
Avg. Volume | 596,317 |
Market Cap | 1.511B |
Beta (5Y Monthly) | 1.10 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Mirum (MIRM) posts positive interim data from two phase IIb studies evaluating volixibat in patients with primary biliary cholangitis and primary sclerosing cholangitis. Stock rises.
Mirum Pharmaceuticals (MIRM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.